^
    PD-L1 overexpression
    Lung Non-Squamous Non-Small Cell Cancer
    Immunotherapy
    Sensitive
    :
    C3
    Lung Cancer - 3wk
    MGAM mutation
    Lung Non-Squamous Non-Small Cell Cancer
    Immunotherapy
    Sensitive
    :
    C3
    Front Pharmacol - 3wk
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    cisplatin
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    atezolizumab
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    bevacizumab + atezolizumab
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    bevacizumab
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    cisplatin + pemetrexed
    Sensitive
    :
    A1
    EGFR mutation
    Lung Non-Squamous Non-Small Cell Cancer
    bevacizumab + erlotinib
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    sintilimab
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    pembrolizumab
    Sensitive
    :
    A1
    EGFR mutation
    Lung Non-Squamous Non-Small Cell Cancer
    nivolumab
    Sensitive
    :
    A1
    ALK mutation
    Lung Non-Squamous Non-Small Cell Cancer
    nivolumab
    Sensitive
    :
    A1
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    pemetrexed
    Sensitive
    :
    A2
    PD-L1 overexpression
    Lung Non-Squamous Non-Small Cell Cancer
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    VC
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    EP
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    CaT
    Sensitive
    :
    A2
    EGFR mutation
    Lung Non-Squamous Non-Small Cell Cancer
    gefitinib
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    bevacizumab
    Sensitive
    :
    A2
    PD-L1 expression
    Lung Non-Squamous Non-Small Cell Cancer
    atezolizumab
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    GemVin
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    GT
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    GC
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    carboplatin + pemetrexed
    Sensitive
    :
    A2
    No biomarker
    Lung Non-Squamous Non-Small Cell Cancer
    GemCarbo
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES